Lin BioScience (6696)

Executive Summary

Lin BioScience is a clinical-stage biopharmaceutical company based in Taiwan, focused on developing oral small-molecule therapies for ophthalmology, oncology, and metabolic diseases. The company's lead candidate, tinlarebant (LBS-008), targets Stargardt disease using a proprietary RBP4 antagonist mechanism and is currently in Phase 3 trials with FDA Fast Track and orphan-drug designations. Additionally, LBS-007 is in early-stage development for acute myeloid leukemia, supported by natural small-molecule inhibitors. With a pipeline spanning preclinical to late-stage trials, Lin BioScience aims to address significant unmet medical needs in rare and hard-to-treat indications. The company went public in Taiwan and has raised approximately $30 million to advance its programs.

Upcoming Catalysts (preview)

• H2 2026Phase 3 interim or top-line data for tinlarebant (LBS-008) in Stargardt disease60% success
• H1 2027Phase 1/2 initial efficacy or safety data for LBS-007 in acute myeloid leukemia40% success
• Q3 2026FDA orphan or fast track designation for additional pipeline candidate70% success